BOARD OF DIRECTORS
Elijah M. Bolotin, PhD,
Elijah is Founder, President and CEO of PharmaIN Corp; his bio can be found on the management page.
Chairman of the Board: John Presutti, MBA
In over 30 years in the pharmaceutical business, Mr. Presutti has served as a financial, marketing, and business development executive at GD Searle and managed commercial activities for Curatek Pharmaceuticals. Most recently he started and ultimately divested Presutti Laboratories after successfully bringing an antibacterial agent to the US Market. He has successfully taken drugs through the regulatory and commercialization process, both for large pharma and as an independent entrepreneur.
Tibor Papp, MD, PhD, MBA
Dr. Papp is currently a Senior Director of Business Development at Shire Pharmaceuticals with global responsibility for generating deals in the therapy areas of hematology-oncology, transplantation and complement-mediated diseases. With 24 years of healthcare, 14 years of pharmaceutical industry, and 10 years of business development experience, Dr. Papp brings substantial expertise to the board of PharmaIN. He has helped global pharma and biotechnology companies develop and adjust their product development and market strategies, and supported them in doing licensing and M&A deals. Dr. Papp is also a qualified orthopedic surgeon, with a PhD from the University of Aberdeen and an MBA from the University of Oxford.
Yuriy Rubin, CFA, MBA
Mr. Rubin is a globally experienced investor and presently is Deputy CEO of Investments and Finance at Irkutsk Oil Company. Previous positions have included Financial Advisor at Prudential Securities and Merrill Lynch. Mr. Rubin holds an MBA from Moscow Russian-American University and a BS in Software Engineering from the University of Radio Engineering and Electronics of Moscow.
Les Salans, MD
Dr. Salans is an internationally recognized expert in the fields of diabetes mellitus, obesity, and endocrinology. He has broad and extensive experience in biomedical research, clinical medicine, and administration in the pharmaceutical industry, academia, and in government. Dr. Salans received his M.D. from the University of Illinois, College of Medicine, followed by internship and residency in internal medicine at Stanford University Medical Center and The Rockefeller University. Previously he has served as VP, Scientific and Academic Affairs and Deputy President for the Sandoz Research Institute, and was Director of the National Institute of Diabetes, Digestive Diseases and Kidney Diseases (NIDDK), NIH. Currently he is Clinical Professor and member of the Clinical Staff at Mt. Sinai, Adjunct Professor of Medicine, Columbia University Medical Center, and serves on the board of Forest Laboratories, Inc.
© PharmaIN 2016